Horner’s syndrome is a condition that occurs when there is a lesion in the sympathetic nerve trunk, resulting in symptoms such as miosis, partial ptosis, enophthalmos, and anhidrosis on the same side as the lesion. The location of the lesion can be determined by the presence and location of anhidrosis. If anhidrosis is present only in the face, it indicates a Preganglionic lesion, which can be caused by conditions such as Pancoast tumors, cervical rib, and thyroid issues. On the other hand, a postganglionic lesion, which can be caused by carotid artery dissection or cavernous sinus thrombosis, results in Horner’s syndrome without anhidrosis. Central lesions, such as those caused by stroke or syringomyelia, result in Horner’s syndrome with anhidrosis of the face, arm, and trunk on the affected side.

Horner’s syndrome is a medical condition that is characterized by a set of symptoms including a small pupil (miosis), drooping of the upper eyelid (ptosis), sunken eye (enophthalmos), and loss of sweating on one side of the face (anhidrosis). The presence of heterochromia, or a difference in iris color, is often seen in cases of congenital Horner’s syndrome. Anhidrosis is also a distinguishing feature that can help differentiate between central, Preganglionic, and postganglionic lesions. Pharmacologic tests, such as the use of apraclonidine drops, can be helpful in confirming the diagnosis of Horner’s syndrome and localizing the lesion.

Central lesions, Preganglionic lesions, and postganglionic lesions can all cause Horner’s syndrome, with each type of lesion presenting with different symptoms. Central lesions can result in anhidrosis of the face, arm, and trunk, while Preganglionic lesions can cause anhidrosis of the face only. postganglionic lesions, on the other hand, do not typically result in anhidrosis.

There are many potential causes of Horner’s syndrome, including stroke, syringomyelia, multiple sclerosis, tumors, encephalitis, thyroidectomy, trauma, cervical rib, carotid artery dissection, carotid aneurysm, cavernous sinus thrombosis, and cluster headache. It is important to identify the underlying cause of Horner’s syndrome in order to determine the appropriate treatment plan.

In Kartagener’s syndrome, the right testicle hangs lower than the left due to situs inversus. Normally, it is the left testicle that hangs lower. This condition can be similar to cystic fibrosis, but patients with cystic fibrosis would have additional symptoms such as diabetes, diarrhoea, and deficiencies in fat-soluble vitamins. It is important to note that there is no indication that the patient is currently taking antibiotics that could affect sperm function and motility.

Understanding Kartagener’s Syndrome

Kartagener’s syndrome, also known as primary ciliary dyskinesia, is a rare genetic disorder that was first described in 1933. It is often associated with dextrocardia, which can be detected through quiet heart sounds and small volume complexes in lateral leads during examinations. The pathogenesis of Kartagener’s syndrome is caused by a dynein arm defect, which results in immotile Ciliary.

The syndrome is characterized by several features, including dextrocardia or complete situs inversus, bronchiectasis, recurrent sinusitis, and subfertility. The immotile Ciliary in the respiratory tract lead to chronic respiratory infections and bronchiectasis, while the defective ciliary action in the fallopian tubes can cause subfertility.

In summary, Kartagener’s syndrome is a rare genetic disorder that affects the motility of Ciliary in the respiratory tract and fallopian tubes. It is often associated with dextrocardia and can lead to chronic respiratory infections, bronchiectasis, recurrent sinusitis, and subfertility. Early diagnosis and management are crucial in preventing complications and improving the quality of life for individuals with this syndrome.

Ovarian cancer is a common malignancy in women, ranking fifth in frequency. It is most commonly diagnosed in women over the age of 60 and has a poor prognosis due to late detection. The majority of ovarian cancers, around 90%, are of epithelial origin, with serous carcinomas accounting for 70-80% of cases. Interestingly, recent research suggests that many ovarian cancers may actually originate in the distal end of the fallopian tube. Risk factors for ovarian cancer include a family history of BRCA1 or BRCA2 gene mutations, early menarche, late menopause, and nulliparity.

Clinical features of ovarian cancer are often vague and can include abdominal distension and bloating, abdominal and pelvic pain, urinary symptoms such as urgency, early satiety, and diarrhea. The initial diagnostic test recommended by NICE is a CA125 blood test, although this can also be elevated in other conditions such as endometriosis and benign ovarian cysts. If the CA125 level is raised, an urgent ultrasound scan of the abdomen and pelvis should be ordered. However, a CA125 test should not be used for screening asymptomatic women. Diagnosis of ovarian cancer is difficult and usually requires a diagnostic laparotomy.

Management of ovarian cancer typically involves a combination of surgery and platinum-based chemotherapy. Unfortunately, 80% of women have advanced disease at the time of diagnosis, leading to a 5-year survival rate of only 46%. It was previously thought that infertility treatment increased the risk of ovarian cancer due to increased ovulation, but recent evidence suggests that this is not a significant factor. In fact, the combined oral contraceptive pill and multiple pregnancies have been shown to reduce the risk of ovarian cancer by reducing the number of ovulations.

The correct result for the quadruple test in a patient with Down’s syndrome is a decrease in AFP and oestriol, and an increase in hCG and inhibin A. This test is recommended by NICE for pregnant patients between 15-20 weeks gestation. If the screening test shows an increased risk, further diagnostic tests such as NIPT, amniocentesis, or chorionic villous sampling may be offered to confirm the diagnosis. It is important to note that a pattern of decreased AFP, decreased oestriol, decreased hCG, and normal inhibin A is suggestive of an increased risk of Edward’s syndrome. Increased AFP, increased oestriol, decreased hCG, and decreased inhibin A or any other combination of abnormal results may not be indicative of Down’s syndrome.

NICE updated guidelines on antenatal care in 2021, recommending the combined test for screening for Down’s syndrome between 11-13+6 weeks. The test includes nuchal translucency measurement, serum B-HCG, and pregnancy-associated plasma protein A (PAPP-A). The quadruple test is offered between 15-20 weeks for women who book later in pregnancy. Results are interpreted as either a ‘lower chance’ or ‘higher chance’ of chromosomal abnormalities. If a woman receives a ‘higher chance’ result, she may be offered a non-invasive prenatal screening test (NIPT) or a diagnostic test. NIPT analyzes cell-free fetal DNA in the mother’s blood and has high sensitivity and specificity for detecting chromosomal abnormalities. Private companies offer NIPT screening from 10 weeks gestation.

If a patient with diabetic ketoacidosis still has significant ketonaemia and acidosis after 24 hours, it is recommended to seek a review from a senior endocrinologist. This is important to consider other potential diagnoses and advise on further treatment. Treatment should aim to reduce blood ketones by approximately 1 mmol/hr and glucose by around 3mmol/hr. By 24 hours, the patient should be eating and drinking normally and can be switched to subcutaneous insulin.

Admission to ICU is not necessary at this point as the patient is relatively stable. The priority is to continue treatment and determine why the current treatment is not working, which can be best achieved with a senior review.

Continuing the current fluid replacement would be inappropriate as patients with DKA should see resolution of their condition after 24 hours of normal treatment. If the patient remains in DKA after this point, a senior review is needed.

Increasing insulin rate, as well as increasing the rate of IV fluids, should not be done without consulting a senior endocrinologist as it may lead to hypoglycaemia or dilutional hyponatraemia, respectively, which could worsen the patient’s condition.

Diabetic ketoacidosis (DKA) is a serious complication of type 1 diabetes mellitus, accounting for around 6% of cases. It can also occur in rare cases of extreme stress in patients with type 2 diabetes mellitus. However, mortality rates have decreased from 8% to under 1% in the past 20 years. DKA is caused by uncontrolled lipolysis, resulting in an excess of free fatty acids that are ultimately converted to ketone bodies. The most common precipitating factors of DKA are infection, missed insulin doses, and myocardial infarction. Symptoms include abdominal pain, polyuria, polydipsia, dehydration, Kussmaul respiration, and acetone-smelling breath. Diagnostic criteria include glucose levels above 13.8 mmol/l, pH below 7.30, serum bicarbonate below 18 mmol/l, anion gap above 10, and ketonaemia.

Management of DKA involves fluid replacement, insulin, and correction of electrolyte disturbance. Most patients with DKA are depleted around 5-8 litres, and isotonic saline is used initially, even if the patient is severely acidotic. Insulin is administered through an intravenous infusion, and correction of electrolyte disturbance is necessary. Long-acting insulin should be continued, while short-acting insulin should be stopped. DKA resolution is defined as pH above 7.3, blood ketones below 0.6 mmol/L, and bicarbonate above 15.0mmol/L. Complications may occur from DKA itself or the treatment, such as gastric stasis, thromboembolism, arrhythmias, acute respiratory distress syndrome, acute kidney injury, and cerebral oedema. Children and young adults are particularly vulnerable to cerebral oedema following fluid resuscitation in DKA and often need 1:1 nursing to monitor neuro-observations.

Treatment for Starvation Ketosis in Alcoholic Abuse Patients

Alcoholic abuse patients with starvation ketosis exhibit low pH, low bicarbonate, low base excess, and compensatory low PaCO2. The appropriate treatment for this condition is intravenous (IV) dextrose. However, it is important to note that glucose can trigger Wernicke’s encephalopathy, a neurological disorder that affects the brain’s ability to process information. Therefore, before administering IV dextrose, patients with alcoholic abuse and starvation ketosis require initial treatment with IV Pabrinex.

In summary, patients with alcoholic abuse and starvation ketosis require prompt medical attention to prevent further complications. The treatment involves administering IV Pabrinex before IV dextrose to avoid triggering Wernicke’s encephalopathy. This approach can help stabilize the patient’s condition and prevent further health complications.

Investigations for Pleural Effusion: Choosing the Right Test

When a patient presents with dyspnoea and a suspected pleural effusion, choosing the right investigation is crucial for accurate diagnosis and management. Here are some of the most appropriate investigations for different types of pleural effusions:

1. Pleural aspirate: This is the most appropriate next investigation to measure the protein content and determine whether the fluid is an exudate or a transudate.

2. Computerised tomography (CT) of the chest: An exudative effusion would prompt investigation with CT of the chest or thoracoscopy to look for conditions such as malignancy or tuberculosis (TB).

3. Bronchoscopy: Bronchoscopy would be appropriate if there was need to obtain a biopsy for a suspected tumour, but so far no lesion has been identified.

4. Echocardiogram: A transudative effusion would prompt investigations such as an echocardiogram to look for heart failure, or liver imaging to look for cirrhosis.

5. Spirometry: Spirometry would have been useful if chronic obstructive pulmonary disease (COPD) was suspected, but at this stage the pleural effusion is likely the cause of dyspnoea and should be investigated.

Study Design for Investigating Adverse Events

The rate of adverse events (AEs) associated with a medication is extremely low, as reported in only 60 patients. Even though yellow cards only account for a small proportion of AEs, a further clinical study or a prospective cohort study is unlikely to provide meaningful outputs over the required period. Mechanistic animal studies can generate a scientific hypothesis, but they cannot confirm the cause of an important AE. On the other hand, a case-control study can provide a readout on risk factors associated with a specific AE compared to control patients over a relatively short period.

In summary, the study design for investigating AEs depends on the number of reported cases and the required period for obtaining meaningful outputs. While clinical and prospective cohort studies are suitable for investigating rare AEs with a large sample size, case-control studies are more appropriate for investigating specific AEs with a smaller sample size over a shorter period. Mechanistic animal studies can provide a scientific hypothesis, but they cannot confirm the cause of an important AE. Therefore, researchers should choose the appropriate study design based on the specific AE and the research question.

Pregnant patients with rheumatoid arthritis (RA) can safely continue using hydroxychloroquine as a treatment without any changes. While the medication does cross the placenta, it has not been shown to cause harm to the fetus at the doses used for RA treatment. Etanercept may be considered if there is a significant flare of disease during pregnancy, but it is not necessary at this time. Leflunomide is strictly contraindicated due to its high teratogenicity. Methotrexate must be discontinued at least 3 months before pregnancy as it is highly teratogenic and abortifacient. Steroids are not necessary for this patient who is not experiencing a flare.

Hydroxychloroquine: Uses and Adverse Effects

Hydroxychloroquine is a medication commonly used in the treatment of rheumatoid arthritis and systemic/discoid lupus erythematosus. It is similar to chloroquine, which is used to treat certain types of malaria. However, hydroxychloroquine has been found to cause bull’s eye retinopathy, which can result in severe and permanent visual loss. Recent data suggests that this adverse effect is more common than previously thought, and the most recent guidelines recommend baseline ophthalmological examination and annual screening, including colour retinal photography and spectral domain optical coherence tomography scanning of the macula. Despite this risk, hydroxychloroquine may still be used in pregnant women if needed. Patients taking this medication should be asked about visual symptoms and have their visual acuity monitored annually using a standard reading chart.

The Levonorgestrel intrauterine system is the appropriate choice for this patient as it is a long-acting contraceptive that can also help prevent heavy menstrual bleeding. It can be inserted immediately as the patient is within 48 hours of childbirth. The Copper intrauterine device should be avoided in those with a history of heavy menstrual bleeding. The lactational amenorrhoea method is only effective for up to 6 months post-partum, and progesterone injections must be repeated every 10-12 weeks, making them unsuitable for this patient’s desire for a long-term contraceptive.

After giving birth, women need to use contraception after 21 days. The progesterone-only pill (POP) can be started at any time postpartum, according to the FSRH. Additional contraception should be used for the first two days after day 21. A small amount of progesterone enters breast milk, but it is not harmful to the infant. On the other hand, the combined oral contraceptive pill (COCP) is absolutely contraindicated (UKMEC 4) if breastfeeding is less than six weeks post-partum. If breastfeeding is between six weeks and six months postpartum, it is a UKMEC 2. The COCP may reduce breast milk production in lactating mothers. It should not be used in the first 21 days due to the increased venous thromboembolism risk post-partum. After day 21, additional contraception should be used for the first seven days. The intrauterine device or intrauterine system can be inserted within 48 hours of childbirth or after four weeks.

The lactational amenorrhoea method (LAM) is 98% effective if the woman is fully breastfeeding (no supplementary feeds), amenorrhoeic, and less than six months post-partum. It is important to note that an inter-pregnancy interval of less than 12 months between childbirth and conceiving again is associated with an increased risk of preterm birth, low birth weight, and small for gestational age babies.